<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p74" style="overflow: hidden; position: relative; background-color: white; width: 908px; height: 1286px;">

<!-- Begin shared CSS values -->
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<!-- End shared CSS values -->


<!-- Begin inline CSS -->
<style type="text/css" >

#t1_74{left:130px;bottom:1196px;letter-spacing:-0.15px;}
#t2_74{left:804px;bottom:1195px;letter-spacing:0.13px;}
#t3_74{left:238px;bottom:1115px;letter-spacing:-0.01px;}
#t4_74{left:238px;bottom:1096px;letter-spacing:-0.01px;}
#t5_74{left:238px;bottom:1076px;letter-spacing:-0.01px;}
#t6_74{left:238px;bottom:1057px;letter-spacing:-0.01px;}
#t7_74{left:238px;bottom:1038px;letter-spacing:-0.01px;}
#t8_74{left:238px;bottom:1018px;letter-spacing:-0.01px;}
#t9_74{left:238px;bottom:999px;letter-spacing:-0.01px;}
#ta_74{left:238px;bottom:979px;letter-spacing:-0.01px;}
#tb_74{left:238px;bottom:960px;letter-spacing:-0.01px;}
#tc_74{left:238px;bottom:940px;letter-spacing:-0.01px;}
#td_74{left:238px;bottom:921px;letter-spacing:-0.01px;}
#te_74{left:238px;bottom:901px;letter-spacing:-0.01px;}
#tf_74{left:238px;bottom:882px;letter-spacing:-0.01px;}
#tg_74{left:238px;bottom:769px;letter-spacing:-0.01px;}
#th_74{left:238px;bottom:735px;letter-spacing:-0.01px;}
#ti_74{left:238px;bottom:715px;letter-spacing:-0.01px;}
#tj_74{left:238px;bottom:696px;letter-spacing:-0.01px;}
#tk_74{left:238px;bottom:677px;letter-spacing:-0.01px;}
#tl_74{left:238px;bottom:657px;letter-spacing:-0.01px;}
#tm_74{left:238px;bottom:638px;letter-spacing:-0.01px;}
#tn_74{left:238px;bottom:618px;letter-spacing:-0.01px;}
#to_74{left:128px;bottom:535px;letter-spacing:-0.2px;}
#tp_74{left:238px;bottom:535px;letter-spacing:-0.24px;}
#tq_74{left:141px;bottom:495px;letter-spacing:-0.01px;}
#tr_74{left:248px;bottom:495px;letter-spacing:0.25px;}
#ts_74{left:143px;bottom:438px;letter-spacing:-0.29px;}
#tt_74{left:250px;bottom:458px;letter-spacing:-0.01px;}
#tu_74{left:250px;bottom:439px;letter-spacing:-0.01px;}
#tv_74{left:248px;bottom:403px;letter-spacing:-0.04px;}
#tw_74{left:238px;bottom:343px;letter-spacing:-0.01px;}
#tx_74{left:238px;bottom:324px;letter-spacing:-0.01px;}
#ty_74{left:238px;bottom:304px;letter-spacing:-0.01px;}
#tz_74{left:238px;bottom:285px;letter-spacing:-0.01px;}
#t10_74{left:238px;bottom:231px;letter-spacing:-0.01px;}
#t11_74{left:238px;bottom:211px;letter-spacing:-0.01px;}
#t12_74{left:489px;bottom:211px;letter-spacing:-0.01px;}
#t13_74{left:238px;bottom:192px;letter-spacing:-0.01px;}
#t14_74{left:238px;bottom:172px;letter-spacing:-0.01px;}
#t15_74{left:238px;bottom:153px;letter-spacing:-0.01px;}
#t16_74{left:202px;bottom:69px;letter-spacing:0.23px;}

.s0_74{font-size:11px;font-family:NotoSans-Regular_7j-;color:#000;}
.s1_74{font-size:12px;font-family:NotoSans-Regular_7j-;color:#000;}
.s2_74{font-size:13px;font-family:NotoSans-Regular_7j-;color:#000;}
.s3_74{font-size:15px;font-family:NotoSans-Regular_7j-;color:#000;}
.s4_74{font-size:28px;font-family:NotoSans-Regular_7j-;color:#000;}
.s5_74{font-size:10px;font-family:NotoSans-Regular_7j-;color:#000;}
.s6_74{font-size:13px;font-family:NotoSans-Regular_7j-_1;color:#000;}
.s7_74{font-size:11px;font-family:NotoSans-Regular_7j-_1;color:#000;}
</style>
<!-- End inline CSS -->

<!-- Begin embedded font definitions -->
<style id="fonts74" type="text/css" >

@font-face {
	font-family: NotoSans-Regular_7j-;
	src: url("fonts/NotoSans-Regular_7j-.woff") format("woff");
}

@font-face {
	font-family: NotoSans-Regular_7j-_1;
	src: url("fonts/NotoSans-Regular_7j-_1.woff") format("woff");
}

</style>
<!-- End embedded font definitions -->

<!-- Begin page background -->
<div id="pg74Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg74" style="-webkit-user-select: none;"><object width="908" height="1286" data="74/74.svg" type="image/svg+xml" id="pdf74" style="width:908px; height:1286px; -moz-transform:scale(1); z-index: 0;"></object></div>
<!-- End page background -->


<!-- Begin text definitions (Positioned/styled in CSS) -->
<div class="text-container"><span id="t1_74" class="t s0_74">7.3. Fundamental considerations of multimodal therapy approaches </span><span id="t2_74" class="t s1_74">74 </span>
<span id="t3_74" class="t s2_74">of such problems by approximately 10% [247]. This observation is of particular importance for </span>
<span id="t4_74" class="t s2_74">patients with an intermediate risk of recurrence (pN1-2 without ECE and primary tumor &gt;5 mm </span>
<span id="t5_74" class="t s2_74">resected in healthy tissue), since in these patients adjuvant radiotherapy alone with 60 Gy in </span>
<span id="t6_74" class="t s2_74">conventional fractionation is sufficient [209, 235-237]. These considerations should be taken </span>
<span id="t7_74" class="t s2_74">into account when deciding which patients are suitable for larynx preservation. If the indication </span>
<span id="t8_74" class="t s2_74">for adjuvant radiochemotherapy is already very likely before a planned laryngectomy, one must </span>
<span id="t9_74" class="t s2_74">expect approximately the same frequency of late effects, including in relation to the ability to </span>
<span id="ta_74" class="t s2_74">swallow, as with primary radiochemotherapy. In patients who are likely to receive only adjuvant </span>
<span id="tb_74" class="t s2_74">radiotherapy, better functional results with regard to swallowing can be expected. In patients </span>
<span id="tc_74" class="t s2_74">for whom adjuvant radiotherapy is not indicated, the best functional results can be expected. In </span>
<span id="td_74" class="t s2_74">return, however, it must also be pointed out that, for various reasons, salvage surgery is not </span>
<span id="te_74" class="t s2_74">always possible after primary radiochemotherapy in cases of primary operability. According to </span>
<span id="tf_74" class="t s2_74">current published observations, this is only possible in every second patient. </span>
<span id="tg_74" class="t s2_74">Inclusion and exclusion criteria for multimodal laryngeal organ preservation protocols </span>
<span id="th_74" class="t s2_74">The following is intended to provide a decision-making aid taking into account the current </span>
<span id="ti_74" class="t s2_74">literature on the indication for multimodal laryngeal organ preservation. The term "laryngeal </span>
<span id="tj_74" class="t s2_74">organ preservation" has now been abandoned and the new term "laryngo-esophageal </span>
<span id="tk_74" class="t s2_74">dysfunction free survival" has been chosen as the endpoint in future studies [223, 227]. The </span>
<span id="tl_74" class="t s2_74">indication for such protocols has been further narrowed and the focus has been directed to T2 </span>
<span id="tm_74" class="t s2_74">and T3 laryngeal carcinomas. In fact, T2 carcinomas are not laryngectomized in Germany, so the </span>
<span id="tn_74" class="t s2_74">indication will focus on the group of T3 carcinomas that are classified as not partially resectable. </span>
<span id="to_74" class="t s3_74">7.3.2.2. </span><span id="tp_74" class="t s3_74">Examinations of voice and swallowing function </span>
<span id="tq_74" class="t s2_74">7.42. </span><span id="tr_74" class="t s0_74">Consensus-based recommendation </span>
<span id="ts_74" class="t s4_74">EEC </span>
<span id="tt_74" class="t s2_74">Voice and swallowing function should be examined and documented pre- </span>
<span id="tu_74" class="t s2_74">therapeutically in larynx-preserving therapy. </span>
<span id="tv_74" class="t s5_74">Strong consensus: 100% </span>
<span id="tw_74" class="t s2_74">The early symptom of laryngeal tumors is hoarseness. This is the reason for clinical </span>
<span id="tx_74" class="t s2_74">examination. In the case that larynx-preserving therapy is planned, the function should be </span>
<span id="ty_74" class="t s2_74">determined pre-therapeutically. Videolaryngostroboscopy and a text recording are </span>
<span id="tz_74" class="t s2_74">considered the minimum requirements for documenting the impaired voice function [248]. </span>
<span id="t10_74" class="t s2_74">Documentation of swallowing function is necessary if there is a history of dysphagia. If oral </span>
<span id="t11_74" class="t s2_74">food intake is not impaired, the patient's </span><span id="t12_74" class="t s6_74">statement and video endoscopic imaging of the larynx </span>
<span id="t13_74" class="t s6_74">and hypopharynx are sufficient for examination and documentation. A flexible endoscopic </span>
<span id="t14_74" class="t s6_74">swallowing examination (FEES) documents whether retention, penetration or aspiration is </span>
<span id="t15_74" class="t s6_74">present [249-251]. </span>
<span id="t16_74" class="t s7_74">Â© Oncology Guideline Program | S3 Guideline Laryngeal Carcinoma | Long Version 1.0 | January 2019 </span></div>
<!-- End text definitions -->


</div>
</body>
</html>
